Chemoprevention-curcumin analog 1.1 (CCA-1.1) or 2,5-bis-(4-hydroxy-3,5-dimethyl benzylidene)-cyclopentanol (Fig. 1) is a new Pentagamavunone-1 (PGV-1) analog synthesized by Utomo et al. (2021) to construct a more compelling candidate for an anticancer drug. Recently, we reported CCA-1.1 potency on colon cancer through a bioinformatic exploration (Wulandari et al., 2020) and its effect against MCF-7 and T47D breast cancer cells (Novitasari et al., 2021; Wulandari et al., 2021a, 2021b). CCA-1.1 showed a better cytotoxic effect than PGV-1 on WiDr colon cancer cells (Utomo et al., 2021). Considering that CCA-1.1 has a similar structure backbone to PGV-1, it might have a comparable or more outstanding anticancer activity. The superiority of PGV-1 revealed a remarkable cytotoxic effect on colon cancer cells beyond many recommended drugs for treating colon cancer such as 5-fluorouracil, cisplatin, and doxorubicin (Meiyanto et al., 2018; Wulandari et al., 2018). More specifically, the antiproliferative activity of PGV-1 is related to a unique G2/M cell cycle arrest, apoptosis, senescence induction, reactive oxygen species (ROS) accumulation (Hermawan et al., 2011; Lestari et al., 2019; Meiyanto et al., 2014, 2018, 2019), and inhibition of nuclear factor kappa B, resulting in the suppression of cyclooxygenase-2 (COX-2) expression in WiDr colon cancer cells (Meiyanto et al., 2018). Conversely, PGV-1’s limitation on physicochemical property obstructs its superiority as an anticancer candidate, and CCA-1.1 might be in place of PGV-1 to be promoted as a more effective anticolon cancer agent.
|Figure 1. Structure of PGV-1 (A) and CCA-1.1 (B).|
[Click here to view]
Developing colon cancer’s chemotherapeutic agents with specific targets and fewer side effects remains a serious issue, which is still a crucial concern in cancer research (Ferlay et al., 2019) even though many attempts in recent years have been achieved to improve the outcome quality of patients (Aiello et al., 2019). An appropriate lifestyle might support patients to live longer with an improved quality of life (Aiello et al., 2019). 5-Fluorouracil (5-FU) is the first-line drug to treat colon cancer, which is usually combined with several agents as leucovorin, irinotecan, oxaliplatin, and levoleucovorin (Goto et al., 2019). Many clinicians also applied the combination of 5-FU and different targeted drugs, including bevacizumab, cetuximab, and panitumumab, to increase its efficacy (Li et al., 2011). For this concern, surgery is not the best option for colon cancer, but new therapies are still inadequate to manage cancer progression. Moreover, severe various side effects caused by several conventional drugs, such as bone marrow suppression, cardiotoxicity, and gastrointestinal toxicities, often shorten life expectancy in patients (Alessandrino et al., 2019). Developing a harmless drug without resistance is such a substantial issue for colon cancer treatment. PGV-1 is a possible choice for this purpose according to its safety, but CCA-1.1 may be a superior alternative.
We utilized the WiDr cell line as the representation of colon cancer, which is featured by p53 mutation, positive COX2 expression, and excessive ROS accumulation (Meiyanto et al., 2018). This cell line contained p21 and correlated with several drug resistance phenomena, such as cisplatin, 5-FU, and paclitaxel (Handayani et al., 2017; Meiyanto et al., 2018), making it suitable as a model for examining a candidate of a specific anticancer agent. The current study is dedicated to observing cell cycle arrest modulation, ROS generation, apoptosis, and senescence occurrence from CCA-1.1’s antiproliferative effect. These results would provide supporting data for developing CCA-1.1 as a potent candidate for chemotherapy.
MATERIALS AND METHODS
CCA-1.1 and PGV-1 were synthesized by Utomo et al. (2021). Doxorubicin was purchased from Sigma-Aldrich.
Cell line and culture conditions
The fibroblast NIH-3T3 cells cultured in a high glucose Dulbecco’s Modified Eagle Medium were contributed by Prof. Masashi Kawaichi, MD. Ph.D., Laboratory of Gene Function in Animals, NAIST, Japan. The colon cancer cells (WiDr) were acquired from the Faculty of Medicine, UGM, Indonesia, and grown in a Roswell Park Memorial Institute 1640 (RPMI-1640) medium. We added 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) (Sigma), sodium bicarbonate (Sigma), streptomycin 150 µg/ml and penicillin 150 IU/ml (Sigma), and 10% v/v fetal bovine serum (FBS) (Sigma) for complementing the culture medium.
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay
To assess cell viability, we utilized an MTT assay. The cells (104 cells/well) in 96-well plates were incubated for 24 hours with CCA-1.1 and PGV-1 at varying doses. The medium culture was replaced with an MTT reagent (Sigma). After 4 hours incubation, 100 µl of 10% sodium dodecyl sulphate (SDS) in 0.01M was added and incubated for 24 hours at room temperature, avoiding light exposure. The next day, we measured the absorbance using a microplate reader at 595 nm (BioRad).
Evaluation of cell cycle profile
Propidium iodide staining was used to assess the cell cycle profiles of WiDr cells (2 × 105 cells/well in 6-well plates) caused by compound treatment. The cell pellets were then collected and processed as a further step as mentioned in the BD Cycletest™ Plus DNA Kit instruction, following measurement using the flow cytometer BD Bioscience C6.
Staining for apoptosis detection
Authors conducted annexin V – propidium iodide (PI) staining-based flow cytometry to examine apoptosis incidence in WiDr cells. The treatment design used is similar to the cell cycle assay. The pellet cells were collected, following cell staining according to the Annexin V-FLUOS Staining Kit (Roche). The stained suspension cells were analyzed by a flow cytometer.
Compounds at concentrations 2 and 4 µM were added to cultured 2 × 105 WiDr cells/well for 24 hours. The next day, cells were washed using phosphate-buffered saline (PBS) and fixed in 4% paraformaldehyde (Sigma). The cells were rewashed in PBS, following adding a staining solution, and placed for incubation at 37°C. Senescence cells were observed after 48 hour incubation and indicated as a green color under a light microscope (CKX-41 Olympus) (400× magnification).
ROS level measurement
Cultured 5 × 104 WiDr cells/well in a 24-well plate were collected in 500 µl PBS containing FBS 10%, followed by 30 minutes staining with 2′,7′-dichlorofluorescein diacetate (DCFDA) (Sigma) 25 mM (incubation at 37°C, 5% CO2 atmosphere). Following the staining incubation, cell suspension was added with samples and doxorubicin (4 hours) at selected concentrations. We utilized the BD Accuri C6™ Flow Cytometer (BD Bioscience) to analyze % fluorescein (ROS level) from 20,000 cells.
In the preliminary investigation, PGV-1 displayed an excellent cytotoxic effect compared to 5-FU on WiDr colon cancer cells (Meiyanto et al., 2018). Currently, we confirm that CCA-1.1 performed greatly in a dose-dependent phenomenon to treat cancer cells compared with PGV-1 against WiDr cells. CCA-1.1 was a stronger cytotoxic agent than PGV-1 (p < 0.01) (Fig. 2), in which PGV-1 and CCA-1.1 at a concentration of 10 µM inhibited cell growth of 47% and 73.5%, respectively. Both compounds showed no growth inhibitory effect (<5%) toward NIH-3T3 cells, a model of a noncancerous cell (Ahlina et al., 2020). From this result, we suggest that CCA-1.1 can possibly combat PGV-1 as an anticancer candidate, owing to the higher cytotoxic effect on WiDr cells and less toxicity on NIH-3T3 cells.
|Figure 2. The profile of cell viability on the treatment of PGV-1 and CCA-1.1 (n = 3). The results are displayed in a graph (mean ± SE). The profile on NIH-3T3 cells (A) and WiDr cells (B). The quantification of IC50 (µM) was presented in a table (C). Statistical analysis was conducted using Student’s t-test (*p < 0.01).|
[Click here to view]
Cell cycle profile
As PGV-1 had a specific cytotoxic property against several cancer cells, we believe that CCA-1.1 would imitate its cytotoxicity. PGV-1 was shown to interrupt cell cycle progression causing arrest at the G2/M phase in WiDr cells (Meiyanto et al., 2014). Here, we figure out that both compounds showed similar characteristics in a cell cycle process interruption. CCA-1.1 and PGV-1 increased cell accumulation at the G2/M phase as shown in the green peak in the flow cytogram (Fig. 3) to a wider area over doxorubicin 100 nM, a chemotherapeutic drug as a positive control that triggers G2/M cell cycle arrest in cancer cells (Meiyanto et al., 2020; Thorn et al., 2011). We also spotted an accumulation at the sub-G1 phase in the treatment of CCA-1.1 (2 and 4 µM) probably representing an apoptosis incidence. We assumed that CCA-1.1 stimulates cell cycle arrest that may subsequently trigger apoptosis.
We then conducted annexin V-PI staining based on a flow cytometry assay to confirm whether sub-G1 arrest caused by CCA-1.1 is indirect cell apoptosis. Apoptosis incidence mainly associates with irreversible cell cycle arrest (Foster, 2008). As the core compound of CCA-1.1, PGV-1 causes increasing apoptosis occurrence in breast cancer (MCF-7 and T47D) and colon cancer cells (WiDr) (Hermawan et al., 2011). We confirmed that CCA-1.1 (2 and 4 µM, 24 hours) effectually stimulates apoptosis in WiDr cells, as did PGV-1 at a similar level (Fig. 4). Considering PGV-1, which established induced cell cycle arrest accompanied by apoptosis, senescence, and ROS generation (Lestari et al., 2019; Meiyanto et al., 2019), CCA-1.1 may have an identical spectrum of activity in suppressing cancer cells. However, further investigation is required.
Cellular senescence incidence
To elucidate the correlation of cell cycle arrest and cellular senescence in the treatment of CCA-1.1, we employed Senescence-Associated (SA)-β-galactosidase assay and employed doxorubicin to trigger senescence in cells (as a positive control) (Kuilman et al., 2010; Yang et al., 2012). We demonstrated that both doses of CCA-1.1 and PGV-1 cause cellular senescence in WiDr cells (p < 0.001) at an equal level with doxorubicin (Fig. 5). We assumed that cellular senescence could be intrinsically related to cell cycle arrest.
Intracellular ROS level
The level of intracellular ROS plays a crucial role in senescence occurrence (Panieri and Santoro, 2016), also closely associated with the principle of the metabolic process (Davalli et al., 2016) and various implications of cellular stress resulting from physiological maintenance of ROS metabolic enzymes in cancer cells (Kashyap et al., 2019). Several studies reported that out-level ROS over the threshold causes cell death or another type of permanent cell arrest as senescence (Ikawati et al., 2020; Larasati et al., 2018). The DCFDA staining, followed by flow cytometry analysis, was used to assess the level of ROS within cells caused by CCA-1.1. We employed doxorubicin as an ROS inducer in cells (Yokoyama et al., 2017). We noted a significant (p < 0.01) elevation of ROS level caused by concentrations of both CCA-1.1 and PGV-1 at a comparable level with doxorubicin (Fig. 6). These results are well consistent with the previous report and CCA-1.1 tends to have the same feature as PGV-1 in terms of ROS generation. In addition, these results also indicate that the increasing ROS level is correlated with senescence evidence and cell cycle arrest.
CCA-1.1 and PGV-1 have a similar structure backbone, but CCA-1.1 is superior due to its improvement of solubility in aqueous solutions and stability, especially in an acidic environment, making it an auspicious candidate to combat PGV-1 as an anticancer candidate. Its stability in acidic solutions offers the possibility of CCA-1.1 to be developed as an oral anticancer drug. Additionally, CCA-1.1 had an equal or greater cytotoxicity on various types of cancer cells, including breast cancer cells (MCF-7/HER2, 4T1, MCF-7, HCC1954, and T47D), leukemia cells (K562), and colon cancer cells (Caco2 and WiDr) (Utomo et al., 2021). In this concern, we provided a piece of fundamental evidence through evaluating CCA-1.1’s anticancer activities on WiDr cells to develop an effective candidate for colon cancer chemotherapy.
|Figure 3. The modulation of cell cycle arrest on the treatment of CCA-1.1 and PGV-1 (n = 3). The cell cycle phase was determined by propidium iodide staining using a flow cytometer (A) as defined in the Materials and Methods section and the results are presented in a graph (mean ± SE).|
[Click here to view]
The current study disclosed the safety of CCA-1.1 on noncancerous NIH-3T3 (selectivity index > 10) cells with greater toxicity on WiDr cells than PGV-1. These results give an insight that CCA-1.1 is possibly a safe agent to treat colon cancer cells. However, whether CCA-1.1 is safe for human consumption or not, such as curcumin (the lead compound) which is an ingredient in a healthy drink for people (Aggarwal and Harikumar, 2009), should be explored further. The cytotoxic effect of CCA-1.1 is more reliable than that of 5-FU on WiDr cells, as previously reported (Meiyanto et al., 2018). Even though 5-FU is a recommended drug for colon cancer therapy, it is described to raise the resistance of colon cancers and have serious side effects to patients (Goto et al., 2019), such as neuropathy, cardiotoxicity, and severe bone marrow suppression. Doxorubicin, paclitaxel, and cisplatin, often used as 5-FU substitutions, were also reported to have similar severe side effects (Florea and Büsselberg, 2011; Thorn et al., 2011). Despite the previous report that doxorubicin (IC50: 1.6 µM) is more potent than CCA-1.1 in WiDr cells (Wulandari et al., 2018), doxorubicin possesses disadvantages including poor solubility and instability under acidic conditions such as the gastric environment, which is not suitable for oral administration. Despite the incompatibility with its oral dosage form, doxorubicin seems to be the most suitable treatment preference since the oral route is comfortable, least invasive, and relatively nonexpensive for patients (Ahmad et al., 2018). A previous study stated that CCA-1.1 was stable in an acidic (gastric) environment, implying the possibility of oral use as a chemotherapy medicine. Since there are many colon cancer types with different attributes, further investigation of CCA-1.1’s activities is required to evaluate the selectivity.
|Figure 4. Apoptosis occurrence on the treatment of CCA-1.1 and PGV-1 on WiDr cells (n = 3). Apoptosis incidence was determined by annexin V-PI staining-based flow cytometry assay (A) and the % cell distribution was quantified into a graph (B) (mean ± SE).|
[Click here to view]
|Figure 5. Senescence incidence in WiDr cells (2 × 105 cells/well/ml) on the treatment of CCA-1.1 and PGV-1 (n = 3). The morphology of senescence cells (A) was observed under a microscope and its percentages were quantified into a graph (mean ± SE). Student’s t-test was used to analyze the differences between treatments (*p < 0.001).|
[Click here to view]
|Figure 6. The level of intracellular ROS in WiDr cells on the treatment of PGV-1 and CCA-1.1 as defined in the Materials and Methods section (n = 3). DCFDA staining-based flow cytometry assay (A) was used to measure the ROS level and the results were presented as a graph (mean ± SE). Student’s t-test was used to analyze the variances between treatments (*p < 0.01; **p < 0.01).|
[Click here to view]
We noted an exciting result that CCA-1.1 mimics PGV-1-inducing cell cycle arrest at the G2/M phase, a complex and complicated stage in cell cycle progression (Rashidian et al., 2007). Lestari et al. (2019) reported that PGV-1 showed a unique inhibition of the cell cycle process at prometaphase on K562 cells (Lestari et al., 2019), which differs from curcumin that target anaphase (Lee and Langhans, 2012) and taxanes or vinca alkaloids that target microtubule spindles (Bates and Eastman, 2017). Defining the detailed targets of CCA-1.1 is an intriguing and challenging issue since the cell cycle elucidates various molecular pathways (Rashidian et al., 2007). Currently, targeting cell cycle regulators are ingenious advancements in cancer treatment (Kaldis and Richardson, 2012).
An arrest in cell cycle progression is intrinsically associated with senescence and apoptosis induction resulting in cell death in cancer cells (Foster, 2008). We presented PGV-1- and CCA-1-induced apoptosis at a similar level, and it is probably correlated with intracellular ROS elevation and senescence incidence. A balanced intracellular ROS level is needed to maintain cellular physiology and growth, especially in cancer cells. Cancer cells could undergo programmed cell death if the ROS level is higher than the threshold (Larasati et al., 2018). Consequently, a set of ROS metabolic enzymes in cancer cells is barely in charge to maintain an appropriate ROS level. At this point, the cytotoxic activity of PGV-1 is complemented by the initial-stage abrogation of several ROS metabolic enzymes (Lestari et al., 2019). Whether CCA-1.1 also mimics PGV-1 on elevating ROS levels by targeting ROS metabolic enzymes in cancer cells should be confirmed. Hence, the accumulation of ROS in cells has an opposite effect on cancer and healthy cells, where increasing ROS at an equal level in healthy cells can induce toxic possibilities in normal tissues and trigger side effects (Davalli et al., 2016). This was essential to explore since the increasing ROS level and senescence may appear in cancer cells and healthy cells.
Our data suggest that CCA-1.1 could be used instead of PGV-1, owing to its excellent aqueous solubility, which may be necessary for drug formulation. However, we have to note that this study was limited just to one kind of cell line, namely WiDr, a colon cell line with a particular molecular characteristic. We still need to examine this new compound against the other colon cell lines for a more comprehensive evaluation. Moreover, as the promising anticancer candidate for colon cancer, CCA-1.1 needs to be tested as a potential tumor-suppressing agent in animal models, including the safety evaluation and defining the molecular target’s mechanism.
In conclusion, we determine that CCA-1.1 accomplished a greater cytotoxic effect than PGV-1 against WiDr cells with a comparable modulation on apoptosis and senescence, triggering arrest in cell cycle, and ROS elevation. Thus, promising features of CCA-1.1 are supported for developing an oral anticolon cancer drug. Some distinct potential target mechanisms have been documented for further exploration to gain a more comprehensive understanding of the anticancer mechanism of CCA-1.1.
The Ministry of Education and Culture, Indonesia, grant no. 3133/UN1.DITLIT/DIT-LIT/PT/2020, and the Center for Research and Development of Medicinal Plants and Traditional Medicine (B2P2TOOT), Tawangmangu, Karanganyar, Indonesia, have supported this study.
Substantial contributions to the design and conception of the work: EM, MI, MK, and JK; acquisition of the data: FW; analysis and interpretation of data: FW, MI, JK, MK, and EM; drafting the work: FW, MI, and EM; revising the work critically: FW, MI, and EM; giving final approval of the manuscript: EM.
This work does not involve subject experiments on animals or humans.
CONFLICT OF INTEREST
There are no conflicts of interest in this study.
This journal remains neutral with regard to jurisdictional claims in published institutional affiliation.
Aggarwal BB, Harikumar KB. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int J Biochem Cell Bio, 2009; 41(1):40–59. CrossRef
Ahlina FN, Nugraheni N, Salsabila IA, Haryanti S, Da’i M, Meiyanto E. Revealing the reversal effect of galangal (Alpinia galanga L.) extract against oxidative stress in metastatic breast cancer cells and normal fibroblast cells intended as a Co- chemotherapeutic and anti-ageing agent. Asian Pac J Cancer Prev, 2020; 21(1):107–17. CrossRef
Ahmad N, Ahmad R, Alam MA, Ahmad FJ. Enhancement of oral bioavailability of doxorubicin through surface modified biodegradable polymeric nanoparticles. Chem Cent J, 2018; 12(1):65. CrossRef
Aiello P, Sharghi M, Mansourkhani SM, Ardekan AP, Jouybari L, Daraei N, Peiro K, Mohamadian S, Rezaei M, Heidari M, Peluso I, Ghorat F, Bishayee A, Kooti W. Medicinal plants in the prevention and treatment of colon cancer. Oxid Med Cell Longev, 2019; 2019:2075614. CrossRef
Alessandrino F, Qin L, Cruz G, Sahu S, Rosenthal MH, Meyerhardt JA, Shinagare AB. 5-Fluorouracil induced liver toxicity in patients with colorectal cancer: role of computed tomography texture analysis as a potential biomarker. Abdom Radiol, 2019; 44:3099–106. CrossRef
Bates D, Eastman A. Microtubule destabilising agents: far more than just antimitotic anticancer drugs: MDA mechanisms of action. Br J Clin Pharmacol, 2017; 83(2):255–68. CrossRef
Davalli P, Mitic T, Caporali A, Lauriola A, D’Arca D. ROS, Cell Senescence, and Novel Molecular Mechanisms in Aging and Age-Related Diseases. Oxid Med Cell Longev, 2016; 2016:3565127. CrossRef
Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, Znaor A, Bray F. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer, 2019; 144(8):1941–53. CrossRef
Florea AM, Büsselberg D. Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects. Cancers, 2011; 3(1):1351–71. CrossRef
Foster I. Cancer: a cell cycle defect. Radiography, 2008; 14(2):144–9. CrossRef
Goto K, Fujiwara Y, Isobe T, Chayahara N, Kiyota N, Mukohara T, Tsubata Y, Hotta T, Tamura K, Yamamoto N, Minami H. Pharmacokinetic study of the oral fluorouracil antitumor agent S-1 in patients with impaired renal function. Cancer Sci, 2019; 110(6):1987–94. CrossRef
Handayani S, Susidarti RA, Jenie RI, Meiyanto E. Two Active Compounds from Caesalpinia sappan L. in Combination with Cisplatin Synergistically Induce Apoptosis and Cell Cycle Arrest on WiDr Cells. Adv Pharm Bull, 2017; 7(3):375–80. CrossRef
Hermawan A, Fitriasari A, Junedi S, Ikawati M, Haryanti S, Widaryanti B, Da’I M, Meiyanto E. PGV-0 and PGV-1 increased apoptosis induction of doxorubicin on MCF-7 breast cancer cells. Pharmacon, 2011; 12(2):55–9. CrossRef
Ikawati M, Jenie RI, Utomo RY, Amalina ND, Ilmawati GPN, Kawaichi M, Edy M. Genistein enhances cytotoxic and antimigratory activities of doxorubicin on 4T1 breast cancer cells through cell cycle arrest and ROS generation. J App Pharm Sci, 2020; 10(10):96–105.
Kaldis P, Richardson HE. When cell cycle meets development. Development, 2012; 139(2):225–30. CrossRef
Kashyap D, Tuli HS, Sak K, Garg VK, Goel N, Punia S, Chaudhary A. Role of reactive oxygen species in cancer progression. Curr Pharmacol Rep, 2019; 5(2):79–86. CrossRef
Kuilman T, Michaloglou C, Mooi WJ, Peeper DS. The essence of senescence. Genes Dev, 2010; 24(22):2463–79. CrossRef
Larasati YA, Yoneda-Kato N, Nakamae I, Yokoyama T, Meiyanto E, Kato J. Curcumin targets multiple enzymes involved in the ROS metabolic pathway to suppress tumor cell growth. Sci Rep, 2018; 8(1):1–13. CrossRef
Lee SJ, Langhans SA. Anaphase-promoting complex/cyclosome protein Cdc27 is a target for curcumin-induced cell cycle arrest and apoptosis. BMC Cancer, 2012; 12(1):44. CrossRef
Lestari B, Nakamae I, Yoneda-Kato N, Morimoto T, Kanaya S, Yokoyama T, Shionyu M, Shirai T, Meiyanto E, Kato JY. Pentagamavunon-1 (PGV-1) inhibits ROS metabolic enzymes and suppresses tumor cell growth by inducing M phase (prometaphase) arrest and cell senescence. Sci Rep, 2019; 9(1):14867. CrossRef
Li Q, Wang D, Li J, Chen P. Clinicopathological and prognostic significance of HER-2/neu and VEGF expression in colon carcinomas. BMC Cancer, 2011; 11(277):1–6. CrossRef
Meiyanto E, Putri DDP, Susidarti RA, Murwanti R, Sardjiman S, Fitriasari A, Husnaa U, Purnomo H, Kawaichi M. Curcumin and its analogues (PGV-0 and PGV-1) enhance sensitivity of resistant MCF-7 cells to doxorubicin through inhibition of HER2 and NF-kB activation. Asian Pac J Cancer Prev, 2014; 15(1):179–84. CrossRef
Meiyanto E, Putri H, Larasati YA, Utomo RY, Jenie RI, Ikawati M, Lestari B, Yoneda-Kato N, Nakamae I, Kawaichi M, Kato JY. Anti-proliferative and anti-metastatic potential of curcumin analogue, pentagamavunon-1 (PGV-1), toward highly metastatic breast cancer cells in correlation with ROS generation. Adv Pharm Bull, 2019; 9(3):445–52. CrossRef
Meiyanto E, Septisetyani EP, Larasati YA, Kawaichi M. Curcumin analog pentagamavunon-1 (PGV-1) sensitizes Widr cells to 5-fluorouracil through inhibition of NF-κB activation. Asian Pac J Cancer Prev, 2018; 19(1):49–56.
Meiyanto E, Susidarti RA, Istighfari JR, Utomo RY, Novitasari D, Wulandari F, Kirihata M. Synthesis of new boron containing compound (CCB-2) based on curcumin structure and its cytotoxic effect against cancer cells. J App Pharm Sci, 2020; 10(2):60–6. CrossRef
Novitasari D, Wulandari F, Jenie RI, Utomo RY, Kato JY, Meiyanto E. A new curcumin analog, CCA-1.1, induces cell cycle arrest and senescence toward ER-positive breast cancer cells. Int J Pharm Res, 2021; 13(1):9. CrossRef
Panieri E, Santoro MM. ROS homeostasis and metabolism: a dangerous liason in cancer cells. Cell Death Dis, 2016; 7(6):e2253. CrossRef
Rashidian J, Iyirhiaro GO, Park DS. Cell cycle machinery and stroke. Biochim Biophys Acta Mol Basis Dis, 2007; 1772(4):484–93. CrossRef
Thorn CF, Oshiro C, Marsh S, Hernandez-Boussard T, McLeod H, Klein TE, Altman RB. Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenet Genom, 2011; 21(7):440–6. CrossRef
Utomo RY, Wulandari F, Novitasari D, Lestari B, Susidarti RA, Jenie RI, Kato JY, Sardjiman S, Meiyanto E. Preparation and cytotoxic evaluation of PGV-1 derivative, CCA-1.1, as a new curcumin analog with improved-physicochemical and pharmacological properties. Adv Pharm Bull, 2021; in press.
Wulandari F, Ikawati M, Meiyanto E, Kirihata M, Hermawan A. Bioinformatic analysis of CCA-1.1, a novel curcumin analog, uncovers furthermost noticeable target genes in colon cancer. Gene Rep, 2020; 21:100917. CrossRef
Wulandari F, Ikawati M, Novitasari D, Kirihata M, Kato JY, Meiyanto E. New curcumin analog, CCA-1.1, synergistically improves the antiproliferative effect of doxorubicin against T47D breast cancer cells. Indonesian J Pharm, 2021a; 31(04):244–56. CrossRef
Wulandari F, Utomo RY, Novitasari D, Ikawati M, Kirihata M, Kato JY, Meiyanto E. The anti-migratory activity of a new curcumin analog, CCA-1.1, against T47D breast cancer cells. Int J Pharm Res, 2021b; 13(01):2877–87. CrossRef
Wulandari N, Meiftasari A, Fadliyah H, Jenie RI. Red Betel Leaves Methanolic Extract (Piper crocatum Ruiz & Pav.) Increases Cytotoxic Effect of Doxorubicin on WiDr Colon Cancer Cells through Apoptosis Induction. Indones J Cancer Chemoprevent, 2018; 9(1):1. CrossRef
Yang MY, Lin PM, Liu YC, Hsiao HH, Yang WC, Hsu JF, Hsu CM, Lin SF. Induction of cellular senescence by doxorubicin is associated with upregulated miR-375 and induction of autophagy in K562 cells. PLoS One, 2012; 7(5):e37205. CrossRef
Yokoyama C, Sueyoshi Y, Ema M, Mori Y, Takaishi K, Hisatomi H. Induction of oxidative stress by anticancer drugs in the presence and absence of cells. Oncol Lett, 2017; 14:6066–70. CrossRef